Drug
18F-rhPSMA-7.3
18F-rhPSMA-7.3 is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph phase_4
1
33%
Ph early_phase_1
1
33%
Ph not_applicable
1
33%
Phase Distribution
1
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Terminated(1)
Detailed Status
Active, not recruiting1
Recruiting1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Early Phase 11 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)
Trials by Status
active_not_recruiting133%
recruiting133%
withdrawn133%
Recent Activity
2 active trials
Showing 3 of 3
recruitingnot_applicable
Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment
NCT07011342
active_not_recruitingphase_4
PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer
NCT06479187
withdrawnearly_phase_1
18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study
NCT05707182
Clinical Trials (3)
Showing 3 of 3 trials
NCT07011342Not Applicable
Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment
NCT06479187Phase 4
PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer
NCT05707182Early Phase 1
18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3